EcoDrugPlus

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSBBBG00000010586
Gene Symbol: KRAS
3 Cross references
203 Possible Orthologues:

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBBBG00000002386
Gene Symbol: LCK
3 Cross references
120 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBBBG00000017506
Gene Symbol: LYN
3 Cross references
197 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSBBBG00000019928
Gene Symbol: MALT1
3 Cross references
197 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSBBBG00000001331
Gene Symbol: MAPKAPK2
3 Cross references
240 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSBBBG00000013207
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSBBBG00000015483
Gene Symbol: MKNK1
3 Cross references
168 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSBBBG00000024717
Gene Symbol: MKNK2
3 Cross references
221 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSBBBG00000023859
Gene Symbol: MCL1
3 Cross references
245 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSBBBG00000013192
Gene Symbol: MDM2
3 Cross references
257 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSBBBG00000009653
Gene Symbol: MPL
3 Cross references
186 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSBBBG00000021971
Gene Symbol: MLST8
3 Cross references
202 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).